| | | |

Personalized Immunotherapy for Mesothelioma: New Research Sheds Lights

ByAlex Strauss
personalized immunotherapy for mesothelioma

New research conducted by a team of German and Austrian scientists could help make personalized immunotherapy for mesothelioma possible. 

Mesothelioma is an incurable cancer caused by exposure to asbestos. Immunotherapy is one of the most promising treatment approaches. 

But immunotherapy drugs like Keytruda do not work for all patients. Scientists do not know exactly why this is. The new study suggests that understanding biomarkers could lead to better outcomes through personalized immunotherapy for mesothelioma. 

How Does Immunotherapy Work?

Immunotherapy is a broad term that means using the patient’s own immune system to fight their cancer. There are many different types of immunotherapy. Some involve stimulating an immune response. Others involve turning off the mechanism that lets mesothelioma cells hide from the immune system. 

That is how Keytruda (pembrolizumab) works. Keytruda is an immune checkpoint inhibitor. It represents a step toward personalized immunotherapy for mesothelioma. Only patients with a certain kind of gene expression respond to Keytruda. 

Patients with higher levels of the protein PD-L1 on their cells can take Keytruda, but it does not work for all of them. Other immunotherapy drugs being tested for mesothelioma include Yervoy and Opdivo. None of them have been FDA-approved specifically for mesothelioma.

Toward More Personalized Immunotherapy for Mesothelioma

The new Austrian study focuses on PD-L1 as a path toward personalized immunotherapy for mesothelioma. Other studies show mesothelioma patients with high PD-L1 expression do not live as long as other patients. The scientists wondered what role biomarkers like PD-L1 play in prognosis and now that could impact treatment. 

They looked at the levels of PD-L1, C-reactive protein (CRP) and Ki-67 protein in 123 cancer patients. CRP and Ki-67 influence cancer growth and spread. 

“Interestingly, Ki-67 index and CRP influenced the prognostic power of PD-L1,” the authors write. 

Patients on an immune checkpoint inhibitor like Keytruda lived longer. But among these patients CRP had more influence on survival than PD-L1 level did. Knowing that could help doctors create personalized immunotherapy for mesothelioma.

“In summary, histological and circulating biomarkers should also be taken into account as potential biomarkers in immune checkpoint inhibitor therapy and they may have an impact on the prognostic power of PD-L1,” they write.  

Malignant pleural mesothelioma is usually fatal within a year, even with the best standard cancer treatment. Personalized immunotherapy for mesothelioma could change the outlook for the 2,500 Americans diagnosed each year. 

Source:

Ghanim, B, et al, “Tumour Cell PD-L1 Expression Is Prognostic in Patients With Malignant Pleural Effusion: The Impact of C-reactive Protein and Immune-Checkpoint Inhibition”, April 1, 2020, Scientific Reports, https://www.nature.com/articles/s41598-020-62813-2


Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Mesothelioma Blood Test May Be Possible
|

Mesothelioma Blood Test May Be Possible

ByAlex Strauss

An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…